C. Schelenz

Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.

R. Kaiser, P. Tremblay, O. Sezer, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.

R. Kaiser, J. Brockmöller, P. Tremblay, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Variations i n t he 5 -Hydroxytryptam ine T ype 3 B R eceptor G ene as P redictors o f t he E fficacy o f A ntiemetic T reatment i n Cancer P atients

R. Kaiser, P. Tremblay, O. Sezer, 2003 .

Meinungsbildnern in Deutschland Prescription Pattern of Aromatase Inhibitors for the Adjuvant Endocrine Therapy of Breast Cancer – A Current Survey of Opinion Leaders in Germany

C. Schelenz, K. Possinger, D. Lüftner, 2009 .